[go: up one dir, main page]

WO2020028572A3 - ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF - Google Patents

ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF Download PDF

Info

Publication number
WO2020028572A3
WO2020028572A3 PCT/US2019/044512 US2019044512W WO2020028572A3 WO 2020028572 A3 WO2020028572 A3 WO 2020028572A3 US 2019044512 W US2019044512 W US 2019044512W WO 2020028572 A3 WO2020028572 A3 WO 2020028572A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
coupled
actrs
trans
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/044512
Other languages
French (fr)
Other versions
WO2020028572A2 (en
Inventor
Kathleen Mcginness
Brant HERRIN
Charles Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogent Biosciences Inc
Original Assignee
Unum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unum Therapeutics Inc filed Critical Unum Therapeutics Inc
Publication of WO2020028572A2 publication Critical patent/WO2020028572A2/en
Publication of WO2020028572A3 publication Critical patent/WO2020028572A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are genetically engineered hematopoietic cells (e.g., genetically engineered hematopoietic stem cells, or genetically engineered immune cells), which co¬ express one or more co- stimulatory polypeptides with an antibody-coupled T cell receptor (ACTR), and uses thereof for enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject in need of the treatment.
PCT/US2019/044512 2018-08-01 2019-07-31 ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF Ceased WO2020028572A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862713162P 2018-08-01 2018-08-01
US62/713,162 2018-08-01
US201862756726P 2018-11-07 2018-11-07
US62/756,726 2018-11-07

Publications (2)

Publication Number Publication Date
WO2020028572A2 WO2020028572A2 (en) 2020-02-06
WO2020028572A3 true WO2020028572A3 (en) 2020-03-05

Family

ID=69231284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/044512 Ceased WO2020028572A2 (en) 2018-08-01 2019-07-31 ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF

Country Status (1)

Country Link
WO (1) WO2020028572A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077785B2 (en) * 2018-08-14 2024-09-03 Sotio Biotech Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
WO2021202801A1 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Augmenting antigen-negative cell death in antigen-targeted immunotherapies
CN117736297A (en) 2020-05-08 2024-03-22 高山免疫科学股份有限公司 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
CN113754778A (en) * 2020-06-05 2021-12-07 上海交通大学 Chimeric antigen receptor targeting CLDN18.2 and uses thereof
CN114349869B (en) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 A bispecific NK cell agonist and its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154628A1 (en) * 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
WO2017161333A1 (en) * 2016-03-18 2017-09-21 Unum Therapeutics Modified chimeric receptors and uses thereof in immune therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154628A1 (en) * 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
WO2017161333A1 (en) * 2016-03-18 2017-09-21 Unum Therapeutics Modified chimeric receptors and uses thereof in immune therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GSCHWENG ET AL.: "Hematopoietic stem cells for cancer immunotherapy", IMMUNOLOGICAL REVIEWS, vol. 257, no. 1, 2014, pages 237 - 249, XP055696993 *

Also Published As

Publication number Publication date
WO2020028572A2 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
WO2020028572A3 (en) ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
MX2025010458A (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
PH12019500750A1 (en) Chimeric antigen receptors for the treatment of cancer
MX2021007368A (en) Anti-transferrin receptor antibodies and uses thereof.
AU2018278321A1 (en) Chimeric antigen receptors targeting FLT3
NZ756763A (en) Engineered transferrin receptor binding polypeptides
BR112021021843A2 (en) Chemically engineered fusion protein compositions and methods of using them
GB2564823A8 (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
WO2019242632A8 (en) Engineered cells and uses thereof
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2016264323A8 (en) Compositions and methods for TCR reprogramming using fusion proteins
EP4461743A3 (en) T cell modification
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MY175869A (en) Compositions and methods for immunotherapy
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
MX2017007138A (en) Methods and compositions for adoptive cell therapy.
WO2014144622A3 (en) Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
AU2016335217A8 (en) Antigen receptors and uses thereof
WO2019136419A3 (en) Compositions and methods for targeting cd99-expressing cancers
MX2022005821A (en) Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19844155

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19844155

Country of ref document: EP

Kind code of ref document: A2